🔍

Procter & Gamble Health Limited (PGHL)

₹5,200.00 +0.99% last close, 16 Oct

📊 NSE: PGHL 🏢 Pharmaceuticals - Multinational 📢 Latest filing: 18 Sep 2026 📝 Analysis written: 14 Dec 2025

Q2 FY27 results

📅 Next results: 02 Nov 2026 (board meeting)

Procter & Gamble Health Limited's board meets on 2 Nov 2026 to consider its Q2 FY27 results (July-September 2026).

In its latest reported quarter, Q1 FY27, Procter & Gamble's revenue was ₹364 Cr (+7.3% year on year, -1.7% on the previous quarter), and net profit ₹96.2 Cr (+45.7% year on year); the operating margin was 27.4%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹364	+7.3%	-1.7%
Operating profit	₹99.6	+10.7%	-26.8%
Net profit	₹96.2	+45.7%	+1.2%
EPS (₹)	57.92	+45.3%	+1.6%
Operating margin	27.4%	—	—

Full quarterly financials → Results calendar →

PGHL delivery percentage

NSE end-of-day data for Fri, 16 Oct 2026

On Fri, 16 Oct 2026, 58.24% of the PGHL shares traded on NSE were taken to delivery, against the stock's own 20-session average of 54.84%. That is close to its usual level.

58.24%Delivery, 16 Oct

54.84%Own 20-session average

0.7×Volume vs its average

₹5,200.00NSE close · +0.99%

Delivery in the last 5 sessions: 57.8% · 56.1% · 65.2% · 62.9% · 58.2%

Delivery across the market →

A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed

📢 Recent Corporate Announcements

PGHL: SEBI Special Window for Physical Share Transfer Re-Lodgement Extended to Feb 4, 2027

🟡 NEUTRAL ⭐ 2/10

REGULATORY 📅 18 Sep 2026, 07:33 PM

Procter & Gamble Health Limited informed stock exchanges regarding an extension of the SEBI special window for re-lodgement of transfer requests for physical shares. Shareholders whose transfer deeds were lodged before April 1, 2019, and rejected or returned due to deficiencies, can now re-lodge them until February 4, 2027. All such re-lodged requests will be processed solely in dematerialized form via its RTA, KFin Technologies Limited. The announcement is procedural and has no material impact on the company's financial results or operating performance.

SEBI special window extended for transfer deeds lodged prior to April 01, 2019
Eligible shareholders can re-lodge physical transfer requests until February 4, 2027
All approved requests will be processed exclusively in dematerialized form
Newspaper advertisements published in Business Standard and Mumbai Lakshdeep on September 16-17, 2026

💡 Physical share holders with rejected transfers prior to April 2019 should submit requisite documents to RTA KFin Technologies before February 4, 2027. Regular market investors have no action required.

PGHL Shareholders Approve Re-appointment of S. Madhavan as Independent Director for 5 Years

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 04 Sep 2026, 05:42 PM

Procter & Gamble Health Limited announced that its shareholders have approved the re-appointment of Mr. S. Madhavan as an Independent Director at the 59th Annual General Meeting held on September 3, 2026. The re-appointment is for a term of five years, effective from November 15, 2026. This formalizes the proposal previously approved by the Board and communicated on May 26, 2026.

Shareholders approved re-appointment of Independent Director Mr. S. Madhavan at the 59th AGM
Re-appointment tenure is for 5 years starting November 15, 2026
AGM was conducted on September 3, 2026 following initial board recommendation on May 26, 2026

💡 Track subsequent corporate governance filings and upcoming quarterly earnings reports for operational updates.

PGHL Shareholders Approve FY26 Dividend, Accounts, and Director Re-Appointments at 59th AGM

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 04 Sep 2026, 05:25 PM

Procter & Gamble Health Limited (PGHL) announced the voting results of its 59th Annual General Meeting held on September 3, 2026. Shareholders approved all 5 resolutions, including the adoption of FY26 financial statements, declaration of final dividend, and ratification of cost auditor remuneration. A total of 1.10 crore votes were polled representing a 66.37% voter turnout across 1.66 crore outstanding shares. Additionally, the special resolution to re-appoint Mr. S. Madhavan as Independent Director for a 5-year term from November 15, 2026, was approved with 99.34% votes in favor.

All 5 resolutions passed with over 99.3% shareholder approval.
Total voter turnout stood at 66.37% (1,10,17,362 votes polled on 1,65,99,382 total shares).
Final dividend and interim dividend confirmation approved with 99.52% votes in favor.
Re-appointment of Independent Director Mr. S. Madhavan approved for a 5-year term effective November 15, 2026 (99.34% approval).

💡 Track the upcoming corporate action dates for final dividend disbursement and monitor upcoming quarterly financial performance.

P&G Health 59th AGM: FY26 Sales Up 16%, PAT Up 30%, Achieved Rs 35 Cr Productivity Savings

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 03 Sep 2026, 05:58 PM

Procter & Gamble Health Limited held its 59th Annual General Meeting on September 3, 2026, presenting full-year FY26 performance and putting standard ordinary and special resolutions to shareholder vote. For FY 2025-26, the company reported 16% sales growth and a 30% rise in PAT (indexed vs comparable 12-month period), supported by Rs 35 crore in productivity savings. Long-term metrics over 5 years reflect a 7% CAGR in net sales and 13% CAGR in PAT, supported by expansion in the vitamins, minerals, and supplements (VMS) market. Key voting items included dividend confirmation and the re-appointment of Independent Director S. Madhavan for a 5-year term starting November 15, 2026.

FY 2025-26 sales grew 16% and PAT increased 30% against the comparable 12-month period
Generated Rs 35 crore in productivity savings across materials, manufacturing, advertising, and overhead in FY 25/26
Reported 5-year net sales CAGR of 7% and PAT CAGR of 13%, with a 43% increase in ROE
Proposed 5-year re-appointment of Independent Director S. Madhavan effective November 15, 2026

💡 Track the upcoming disclosure of final scrutinizer voting results within 2 working days to confirm resolution approvals.

PGHL Concludes 59th AGM; Reports 16% Sales and 30% PAT Growth for FY26 on Like-for-Like Basis

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 03 Sep 2026, 05:51 PM

Procter & Gamble Health Limited concluded its 59th Annual General Meeting on September 3, 2026. In its presentation, the company highlighted FY 2025-26 sales growth of 16% and PAT growth of 30% on a comparable 12-month basis. The company achieved Rs 35 crore in productivity savings across materials, manufacturing, overhead, and promotions in FY 25/26. Over a 5-year horizon, PGHL reported a 7% CAGR in net sales and a 13% CAGR in PAT.

Delivered +16% Sales growth and +30% PAT growth in FY 2025-26 (indexed vs comparable 12M prior period)
Achieved Rs 35 crore in productivity savings across supply chain and overheads in FY 25/26
Reported 5-year CAGR of 7% for Net Sales and 13% for PAT, with a 43% increase in ROE
Noted steady Indian VMS category growth of 9% CAGR over the last 3 years
Proposed re-appointment of Mr. S. Madhavan as Non-Executive Independent Director for 5 years

💡 Track the upcoming disclosure of AGM voting results via exchanges and monitor quarterly margin sustainability given the Rs 35 crore productivity cost controls.

PGHL Schedules 59th AGM for Sept 3, 2026; Releases FY 2025-26 Annual Report

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 12 Aug 2026, 05:12 PM

Procter & Gamble Health Limited (PGHL) has scheduled its 59th Annual General Meeting for September 3, 2026. The company released its FY 2025-26 Annual Report, highlighting a focus on its 'Integrated Growth Strategy' across its Vitamin, Mineral, and Supplement (VMS) portfolio. Financial notes reveal an increase in share-based payment expenses to 188 lakhs from 81 lakhs in the previous period. The company maintains a strong balance sheet with a high ROCE of 84% and minimal debt of 9 Cr.

59th Annual General Meeting scheduled for September 3, 2026, at 2:30 PM via electronic mode.
Share-based payment expense for FY 2025-26 rose to 188 lakhs compared to 81 lakhs in the previous nine-month period.
Employees purchased 3,630.27 shares of the ultimate holding company (P&G USA) at a weighted average fair value of 15,066.41 per share.
Company contribution to the International Stock Ownership Plan increased to 149.62 lakhs from 93.22 lakhs year-on-year.
Management confirmed a 1.4x increase in absolute sales volume over the last 5 years through manufacturing transformation.

💡 Investors should review the Annual Report for management's outlook on rural market expansion and the impact of Drug Price Control Order (DPCO) pricing on the core VMS brands like Neurobion.

PGHL Revises Record Date to August 27, 2026, for Final Dividend and 59th AGM

🟡 NEUTRAL ⭐ 3/10

DIVIDEND 📅 10 Aug 2026, 07:08 PM

Procter & Gamble Health Limited (PGHL) has updated its schedule for the 59th Annual General Meeting (AGM) and the associated final dividend. The record date, previously set for August 21, 2026, has been revised to August 27, 2026. The AGM is now scheduled for September 3, 2026, and the final dividend, if approved, will be paid to eligible shareholders by September 27, 2026. This is a procedural adjustment to the corporate calendar.

Revised Record Date for dividend and AGM eligibility is August 27, 2026
Original Record Date was previously intimated as August 21, 2026
59th Annual General Meeting (AGM) scheduled for Thursday, September 3, 2026
Final dividend payment deadline set for September 27, 2026, subject to member approval
Company maintains a high ROCE of 84.0% and low debt of Rs 9 Cr as per latest context

💡 Investors should ensure they hold the stock by the new record date of August 27, 2026, to be eligible for the final dividend. Monitor the outcome of the AGM on September 3, 2026, for formal dividend approval.

45% PAT growth to ₹96 cr in Q1 FY27; Operational PAT up 9% on ₹356 cr sales

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 06 Aug 2026, 02:04 PM

Procter & Gamble Health Limited (PGHL) reported a 7% YoY increase in sales to ₹356 crores for the quarter ended June 30, 2026. Reported Profit After Tax (PAT) surged 45% to ₹96 crores, significantly aided by one-time proceeds from the sale of an immovable asset. Excluding this one-time gain, operational PAT grew by 9% to ₹72 crores. The company continues to leverage its strong brands like Neurobion and Evion, maintaining a high ROCE of 84% and a very low debt-to-equity ratio of 0.02.

Sales increased by 7% YoY to ₹356 crores for the quarter ended June 30, 2026.
Reported PAT grew 45% YoY to ₹96 crores, including one-time asset sale proceeds.
Operational PAT (excluding one-time items) rose 9% YoY to ₹72 crores.
The company maintains a high Return on Capital Employed (ROCE) of 84.0%.
Debt remains minimal at ₹9 crores against a net worth of ₹525 crores.

💡 Investors should monitor the sustainability of the 9% operational PAT growth and track how the company manages pricing under DPCO regulations to maintain margins in the VMS segment.

PGHL Q1 Results: Net Profit Rises 45% to ₹96.15 Cr, Aided by ₹31.8 Cr Property Sale

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 06 Aug 2026, 01:58 PM

Procter & Gamble Health Limited (PGHL) reported a steady 7.4% YoY revenue growth to ₹363.71 Cr for the quarter ended June 30, 2026. Net profit surged 45.3% YoY to ₹96.15 Cr, though this was significantly bolstered by a one-time exceptional gain of ₹31.80 Cr from the sale of its Worli office premises. Excluding this gain, Profit Before Tax (PBT) stood at ₹97.31 Cr, a 9.6% increase over the ₹88.81 Cr reported in the same quarter last year. The company continues to operate with a very strong ROCE of 84% and minimal debt of ₹9 Cr.

Revenue from operations grew 7.4% YoY to ₹363.71 Cr from ₹338.74 Cr.
Net profit increased to ₹96.15 Cr, up from ₹66.18 Cr in the corresponding quarter last year.
Realized an exceptional gain of ₹31.80 Cr from the sale of Worli office property for ₹33.34 Cr.
Employee benefit expenses rose 7.8% YoY to ₹60.39 Cr.
Basic EPS (after exceptional items) improved to ₹57.92 from ₹39.87 YoY.

💡 Investors should focus on the core operational performance excluding the one-time property gain to assess sustainable growth. Watch for the impact of DPCO pricing regulations on margins in the upcoming quarters.

PGHL Sets August 27, 2026 as Record Date for Final Dividend and Reschedules AGM

🟡 NEUTRAL ⭐ 3/10

DIVIDEND 📅 15 Jul 2026, 06:29 PM

Procter & Gamble Health Limited (PGHL) has revised the schedule for its 59th Annual General Meeting (AGM) and the associated record date for dividend eligibility. The AGM is now scheduled for September 3, 2026, with the record date for the final dividend set as August 27, 2026. Shareholders appearing on the register as of the record date will be eligible for the final dividend, which is slated for payment by September 27, 2026, subject to shareholder approval. This update follows a previous communication dated May 26, 2026.

Revised 59th Annual General Meeting (AGM) date is September 3, 2026
Record date for final dividend eligibility is fixed for August 27, 2026
Final dividend payment deadline is September 27, 2026, if approved
Company maintains a high ROCE of 84.0% and low debt of Rs 9 Cr

💡 Investors should note the August 27, 2026 record date to ensure eligibility for the final dividend. Monitor the AGM outcome on September 3 for the formal approval of the dividend amount.

June 30, 2026: PGHL Submits Routine Share Dematerialization Certificate

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 03 Jul 2026, 06:02 PM

Procter & Gamble Health Limited (PGHL) has filed its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The filing confirms that share certificates received for dematerialization during the quarter ended June 30, 2026, were processed and the records updated with depositories (NSDL/CDSL). This confirmation was provided by the company's Registrar and Transfer Agent, Kfin Technologies Limited. This is a standard administrative filing required for all listed entities to ensure the integrity of electronic shareholding records.

Covers the compliance requirements for the quarter ended June 30, 2026
Confirmation certificate issued by Registrar Kfin Technologies Limited on July 1, 2026
Details furnished to stock exchanges within the prescribed regulatory time period

💡 No action is required as this is a routine regulatory filing. Investors should monitor upcoming quarterly financial results for fundamental business performance.

PGHL Announces ₹45 Final Dividend for FY 2025-26 and Issues TDS Guidelines

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 26 Jun 2026, 06:23 PM

Procter & Gamble Health Limited (PGHL) has recommended a final dividend of ₹45 per equity share for the financial year 2025-26, subject to shareholder approval. The company has released detailed instructions regarding Tax Deducted at Source (TDS) on this dividend, which is taxable in the hands of shareholders. Resident shareholders with a valid PAN will be subject to a 10% TDS, while those without a valid PAN or linked Aadhaar will face a 20% deduction. Shareholders must submit relevant tax exemption documents or residency certificates by August 12, 2026, to ensure the correct tax rate is applied.

Recommended a final dividend of ₹45 per equity share of face value ₹10 for FY 2025-26.
Standard TDS rate of 10% for resident shareholders with a valid PAN and linked Aadhaar.
Higher TDS rate of 20% for resident shareholders with invalid PAN or missing Aadhaar-PAN linkage.
No TDS for individual resident shareholders if the total dividend for the year does not exceed ₹10,000.
Deadline for submitting tax-related declarations and documents is August 12, 2026.

💡 Shareholders should verify that their PAN is correctly updated and linked with Aadhaar in their demat accounts to avoid a higher 20% tax deduction. Eligible investors seeking tax exemptions should submit Form 121 or other required documents on the KFintech portal before the August 12 deadline.

PGHL Announces Trading Window Closure from July 1, 2026, for Q1 Financial Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 26 Jun 2026, 04:18 PM

Procter & Gamble Health Limited (PGHL) has officially notified the stock exchanges regarding the closure of its trading window starting July 1, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the declaration of unaudited financial results for the quarter ending June 30, 2026. The restriction applies to all Directors and designated employees to prevent insider trading. The window will remain closed until 48 hours after the financial results are publicly disclosed.

Trading window closure effective from July 1, 2026.
Closure is related to the unaudited financial results for the quarter ended June 30, 2026.
Restriction applies to Directors and designated employees of the company.
Trading window will reopen 48 hours after the publication of the financial results.

💡 This is a routine regulatory filing with no direct impact on stock fundamentals; investors should wait for the upcoming Q1 earnings release to assess performance.

PGHL Announces Senior Management Restructuring and New Marketing Leader Appointment

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 25 Jun 2026, 07:55 PM

Procter & Gamble Health Limited (PGHL) has announced a strategic restructuring of its senior management team effective July 1, 2026. The company has appointed Mr. Shine Matthew Sunny, who brings over 15 years of experience, to lead Marketing Strategy, Commercial Excellence, and E-commerce. Simultaneously, three veteran internal leaders with a combined experience of over 80 years—Mr. Abhijit Roy, Mr. M. Padmakar Rao, and Mr. Nilesh Barbade—have been reassigned to lead various sales regions and institutional business segments. This realignment aims to optimize the company's sales strategy and digital commerce capabilities.

Mr. Shine Matthew Sunny appointed as Marketing Strategy and Planning leader with 15+ years of experience at P&G and Reckitt.
Mr. Abhijit Roy (30+ years experience) transitioned to Sales Leader for South and East regions and Exports.
Mr. M. Padmakar Rao (25+ years experience) reassigned as Sales Leader for North & West regions and Institutional Business.
Mr. Nilesh Barbade (26+ years experience) moved to the role of Sales Leader (Trade) to leverage deep pharma and OTC expertise.

💡 Investors should view this as a routine organizational optimization; monitor if this leadership realignment improves regional sales performance or e-commerce growth in future earnings.

PGHL Reports 30% PAT Growth to ₹327 Crore in FY26; Sales Up 16% to ₹1,400 Crore

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 18 Jun 2026, 11:36 PM

Procter & Gamble Health Limited (PGHL) delivered a robust financial performance for the fiscal year ended March 31, 2026, with sales reaching approximately ₹1,400 crore, a 16% year-on-year increase. Profit After Tax (PAT) surged by 30% to ₹327 crore, supported by a 16% growth in the top line and significant productivity gains. The company is focusing on 'irresistible superiority' through new launches like Livogen Iron Gummies and Neurobion Nerve Pain Relief Cream to address high-prevalence health gaps in India. Management also reported ₹35 crore in productivity savings, which are being reinvested into brand building and margin expansion.

Annual sales grew 16% YoY to reach approximately ₹1,400 crore for the fiscal year ended March 2026.
Profit After Tax (PAT) increased by 30% YoY to ₹327 crore, significantly outpacing revenue growth.
Achieved ₹35 crore in savings through targeted productivity and efficiency programs across the value chain.
Introduced high-potential innovations including Livogen Iron Gummies, Neurobion Nerve Pain Relief Cream, and Evion L5000.
Maintained strong market position in Vitamin B, Iron, and Vitamin E categories with brands like Neurobion, Livogen, and Evion.

💡 Investors should take note of the strong margin expansion and the company's ability to grow its bottom line at nearly double the rate of its top line. The successful rollout of new formats like gummies and topical creams indicates a strong innovation pipeline that could drive future market share gains.

View All PGHL Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

The company delivered sales of INR 319 Cr in Q2 FY26, representing a 3% YoY growth. For the 9-month fiscal year ended March 31, 2025, sales reached INR 918 Cr, up 8% compared to the same period in the previous year. The Vitamins, Minerals, and Supplements (VMS) segment remains the core driver, with Neurobion reach expanding 1.4x over 5 years.

Geographic Revenue Split

While specific regional percentage splits are not disclosed, the company is aggressively targeting rural India, aiming to increase coverage and leverage e-commerce to broaden portfolio availability across the country.

Profitability Margins

Net profit margins expanded by 200 basis points over the last 5 years. For the 9-month fiscal ended March 31, 2025, Profit After Tax (PAT) was INR 234.41 Cr, representing a 25.5% net margin. Q2 FY26 PAT stood at INR 89 Cr, up 8% YoY.

EBITDA Margin

Historical data shows operating profit (OPBDIT/OI) at 17.4% in CY2018, up from 13.5% in CY2017. Recent structural profit growth was reported at 27% for the 9-month fiscal year 2024-25, driven by productivity efforts and sales growth.

Capital Expenditure

Not disclosed in absolute INR Cr for future periods; however, the company focuses on 'maximizing return on assets' and has seen Return on Equity (ROE) increase 3x over the past 5 years (with a 34% increase specifically noted in recent trends).

Credit Rating & Borrowing

The company maintains a strong financial profile with a credit rating of [ICRA]AA (Stable). It operates with a net cash position and zero total debt (Total Debt/TNW of 0.0), resulting in negligible borrowing costs.

⚙️ Operational Drivers

Raw Materials

Specific raw materials include active pharmaceutical ingredients (APIs) for Vitamins (E, B12, B1, B6), minerals, and supplements. While exact cost percentages per material are not disclosed, the 'Vitamins' segment represents a high product concentration for the company.

Import Sources

The company leverages the global supply chain of its parent, The Procter & Gamble Company (P&G), and historically sourced technology and materials from Merck KGaA (Germany) following the 2018 acquisition.

Key Suppliers

Key suppliers include P&G global affiliates and Merck KGaA (under historical business transfer agreements).

Capacity Expansion

Current capacity is not disclosed in MT; however, the company has transformed its manufacturing operations and go-to-market model over the last 5 years to support a 1.4x increase in absolute sales volume.

Raw Material Costs

Raw material costs are managed through a 'productivity muscle' that delivered over INR 40 Cr in savings during the 2024-25 fiscal year. These savings are reinvested into product superiority and brand building.

Manufacturing Efficiency

Efficiency is driven by 'continuous technology upgrades' from the parent company, P&G, focusing on process efficiencies and cost-effectiveness in production.

Logistics & Distribution

The company has added nearly 100,000 new stores for its Neurobion brand over 5 years, indicating a massive expansion in distribution logistics and retail activation.

📈 Strategic Growth

Expected Growth Rate

Growth Strategy

Growth will be achieved through the 'Integrated Growth Strategy' which focuses on five vectors: Portfolio, Superiority, Productivity, Constructive Disruption, and an Agile Organization. Specific actions include expanding rural coverage, leveraging e-commerce, and launching innovations in the VMS category. The company achieved INR 40 Cr in productivity savings to fuel reinvestment in brand communication and retail execution.

Products & Services

Over-the-counter (OTC) and prescription medicines including vitamins, minerals, and supplements (VMS), and nasal decongestants.

Brand Portfolio

Neurobion, Livogen, Polybion, Evion, Nasivion, and Seven Seas.

New Products/Services

New innovations in the VMS category contributed to the 3% sales growth in Q2 FY26; specific revenue contribution percentages for new launches are not disclosed.

Market Expansion

Plans involve increasing 'Coverage in Rural Areas' and broadening the digital shelf via e-commerce to reach more healthcare practitioners (HCPs) and consumers.

Market Share & Ranking

The company is a major player in the Indian VMS market, with Neurobion being a leading brand in the vitamin B segment.

Strategic Alliances

The company benefits from a technology license and support agreement with its parent, The Procter & Gamble Company (P&G), providing access to cutting-edge R&D and manufacturing processes.

🌍 External Factors

Industry Trends

The healthcare sector is shifting toward preventative care and supplements. The industry is evolving through digital health and e-commerce expansion. PGHL is positioning itself by strengthening its 'digital shelf' and increasing engagement with healthcare practitioners (HCPs).

Competitive Landscape

Key competitors include other major pharmaceutical and FMCG players in the VMS and OTC space; competition is based on brand reach, doctor prescriptions, and retail availability.

Competitive Moat

The moat is built on 'superior brand legacy' (e.g., Neurobion, Evion) and access to P&G's global 'advanced technology' and 'productivity muscle.' These are sustainable due to high consumer trust and the high cost of entry for pharmaceutical manufacturing and distribution.

Macro Economic Sensitivity

The company is sensitive to rural consumption trends; IMF projects India's economy to grow by 6.8% in 2024 and 6.5% in 2025, which is expected to support private consumption and demand for health products.

Consumer Behavior

There is an increasing consumer focus on 'holistic health' and 'preventative supplementation,' which directly benefits the company's VMS-heavy portfolio.

Geopolitical Risks

Trade barriers or global supply chain disruptions could impact the import of specialized pharmaceutical ingredients required for their VMS portfolio.

⚖️ Regulatory & Governance

Industry Regulations

Operations are heavily governed by the Drugs and Cosmetics Act and the Drug Price Control Order (DPCO), which regulates the ceiling prices of essential medicines, directly impacting the pharmaceutical portfolio's revenue growth.

Environmental Compliance

The company integrates environmental sustainability into its 'Citizenship' efforts, seeking to reduce the footprint of operations and enable consumers to do the same.

Taxation Policy Impact

The effective tax rate for FY 2024-25 was approximately 24.8% (Tax of INR 77.21 Cr on PBT of INR 311.62 Cr).

Legal Contingencies

The company reported 'Nil' complaints regarding sexual harassment during the fiscal year. Other specific pending litigation values in INR are not disclosed in the provided documents.

⚠️ Risk Analysis

Key Uncertainties

Regulatory changes in drug pricing (DPCO) and high product concentration in the Vitamin category (VMS) are the primary uncertainties that could impact margins by 5-10% if more products are brought under price control.